Member Info for ROCKZ

Enough money in the pot to keep Accustem on track whilst the structure of the company is built.
TLSA is well cashed up for pretty much the next year.
Other small cap companies in the sector will need to find answers pronto as their cash runway shortens.
I will keep loading up on the companies in this sector who are undervalued, with a cash runway taking them into next year.

True. It feels like it has disappeared in Europe now though.
The BOD may have allocated their funds elsewhere now. The markets are uncertain and they may struggle to raise at a reasonable price so I think they are being fairly prudent rather than fighting on all fronts.

Some of these small cap biotech/life science companies are sitting ducks for the big pharma companies right now.
Companies like Merck and Bristol Myers Squibb have had a strong year and bucked the trend.
M and A was down last year, cash reserves are strong so it’s only a matter of time until they pounce for the smaller companies with the best potential.

Hi Bluebelly,
It remains to be seen exactly what income is generated from the precision bio deal.
The terms of the deal have yet to be clarified to investors.
The precision bio SP has also taken a battering recently.
I know they are paying a fee to use Foralumab in their CAR-T therapy research but I think we are only really going to see the serious financial benefit once Precision manage to commercialise this particular version of CAR-T therapy.

TLSA had $40m cash at the end of January 2022.
Once trials start cash burn will match Aridis at $7m a quarter.
This still takes the company through Q1/Q2 2023.

TLSA don’t need to raise until 2023 with many inflection points along the way so the BOD will be feeling comfortable financially.
I watched the Aridis pharma presentation last night. They are burning cash at a rate of $7.1m per quarter. Admittedly they are in Phase 3.
TLSA are burning cash at approximately $3m per quarter.
Nothing to worry about here, that $57m raise was a very smart move indeed.

I’m not sure the share buy back from the company has even began yet..
Laura Fonda was the one topping up recently. Volume doesn’t suggest the company were also buying.

Bloodbath on the Nasdaq today, not just TLSA, across the board.

Good sign that she’s buying, she may know more than us.
Anyone else still buying here apart from Laura Fonda?
I suspect everyone’s fully loaded…

Fill us in please Paul on the B Riley call, what was said?
It’s the first call I’ve missed in the last couple of years.

Saying that, I’m not sure Robin Hood is available to uk investors yet. I know there were plans for it to be made available to us but I’m not sure where this is at.

Cheers Appletree, keep me posted if you get any luck buying, I’m a bit tied up for the next few weeks.
GC buying is a good sign.
I wonder if anyone has tried buying through RobinHood?

From listening to GC talking about the AIM in the fairly recent past, I would be amazed to see him float on the AIM again, given the option. He’s clearly not a fan and believes companies are undervalued compared to the Nasdaq.
Let us know if you get any joy in your search for buying ACUT, I would be interested in taking some more.

Hi, yes, I’ve got some of my Accustem holding with Barclays.
I’ve been having ongoing dialogue with them and agreed my end that a share certificate would be acceptable although this is yet to be confirmed.
They seem to struggle to get the answers but I’ve managed to get them to void my charges for now so I will just see how things develop.

78% up here in the last month and plenty of upside to come.
Gabrielle has the Accustem dream team in place which has had a positive impact on the TLSA share price along with investors moving back to the safer haven of the life sciences sector on the Nasdaq.
Accustem Nasdaq listing to come which will increase the value here as the return in positive sentiment for the BOD continues.

Yes Bo, correct, 40p.

You can trade on the HL app, you just have to do your first TLSA trade on the HL website then the app will recognise TLSA.

The HL consolidation has been carried out to TLSA.

Apologies Bluebelly, basically an article saying that investors are retreating from European markets due to the uncertainty caused by the Ukraine conflict.
The Nasdaq/US stocks are seen as a safer option at the moment.
GC could not have predicted what was to happen with the Russians but the move to the Nasdaq is looking even wiser now.

https://amp.ft.com/content/7614f65b-f584-4f76-9c3e-8d0d7f211d87